Lataa...
Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents
It is highly demanded and still a big challenge to develop an effective formulation for immunochemotherapy against advanced tumors. We have previously reported a PEG-NLG-based immunostimulatory nanocarrier (PEG(2k)-Fmoc-NLG919) for codelivery of an IDO1 inhibitor (NLG919) and a chemotherapeutic agen...
Tallennettuna:
| Julkaisussa: | Mol Pharm |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6452437/ https://ncbi.nlm.nih.gov/pubmed/30222360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.8b00717 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|